Sakar Healthcare Ltd
NNSE:SAKAR951.80
INR
+47.00
(+5.19%)
ISIN
INE732S01012
Return %
Stock
S&P 500
1Y
160.87
14.20
3Y
165.50
81.12
5Y
524.34
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Sanjay Surendra Shah
- Full Time Employees
- 435
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 406, Silver Oaks Comm. Complex Ahmedabad GU India 380007
- IPO Date
- Oct 14, 2016
- Website
- sakarhealthcare.com
- Similar Companies
- Business
- Sakar Healthcare Limited, incorporated in 2004 and headquartered in Ahmedabad, Gujarat, India, manufactures and markets pharmaceutical formulations including liquid orals; cephalosporin tablets and capsules; dry powder syrups and injections; liquid injectables in small volume parenterals such as ampoules and vials; lyophilized injections; and oral solid dosages across more than 23 therapeutic areas encompassing antacids, antimalarials, anticoagulants, laxatives, anthelmintics, bronchodilators, anaesthetics, antidepressants, sedatives, adrenergics, anti-infectives, diuretics, oxytocics, analgesics, antiemetics, antipsychotics, antifungals, proton pump inhibitors, anticonvulsants, anti-inflammatories, antihistamines, and multivitamins; the company additionally produces oncology products covering oral solid dosages, liquid and lyophilized injections, active pharmaceutical ingredients, contract development and manufacturing organization services, and contract research and manufacturing services. Sakar Healthcare exports to Southeast Asia, Africa including Anglo and Francophone regions, MENA countries, Latin America, the European Union, the United States, and emerging markets such as Angola, Belarus, Belize, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Cambodia, Cameroon, Chile, Congo, Costa Rica, Cote d'Ivoire, DR Congo, El Salvador, Ethiopia, Gabon, Georgia, Ghana, Guatemala, Guinea, Guyana, Haiti, Honduras, Iraq, Jamaica, Kenya, Kyrgyzstan, Liberia, Libya, Madagascar, Malawi, Mali, Mauritius, Mozambique, Myanmar, Namibia, Nepal, Nicaragua, Niger, Nigeria, Panama, Paraguay, Peru, Philippines, Senegal, Sierra Leone, Sri Lanka, Sudan, Tajikistan, Tanzania, Thailand, Togo, Trinidad, Turkmenistan, Uganda, Uzbekistan, Vietnam, Yemen, Zambia, and others, while serving domestic institutional and retail customers through principal-to-principal sales and contract manufacturing for multinational pharmaceutical companies. In February 2025, the company entered a contract manufacturing agreement with Accord Healthcare Limited to support oncology scale-up; in November 2025, Sakar Healthcare secured nine new marketing authorizations for oncology products targeting gastrointestinal, colon, rectal, pancreatic, prostate, bladder, breast, ovarian, lung, blood, and bone marrow cancers, elevating its total to eleven across the European Union and emerging markets to boost commercial exports; FY2025 revenues rose 16% to Rs 178 crore propelled by an 80% surge in oncology sales to Rs 36 crore from its new facilities for formulations operational since October 2021, APIs since July 2022, and injectables since April 2023; the company maintains EU-GMP, WHO-GMP, ISO 9001:2015, INVIMA-Colombia, and Health Canada certifications at its Changodar facility near Ahmedabad, with a wholly-owned subsidiary Sakar Oncology Private Limited.